Skip to content

Economic Evaluation of Vancomycin Therapeutic Drug Monitoring: A National Multicentre, Retrospective Study

Economic Evaluation of Vancomycin Therapeutic Drug Monitoring: A National Multicentre, Retrospective Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051427
Enrollment
Unknown
Registered
2021-09-23
Start date
2022-03-01
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

Patients treated by vancomycin alone or combination use:None
Patients treated without vancomycin:none

Sponsors

Fujian Medical University Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients treated by vancomycin in single or combination use: 2. Unlimited gender and age; 3. The duration of vancomycin is above 3 days; 4. The method of administration is intravenous infusion or micro-infusion pump push injection.

Exclusion criteria

Exclusion criteria: 1. Patients treated by anti-gram-positive agents within 72 hours before enrollment, such as norvancomycin,teicoplanin, linezolid, fusidic acid, tigecycline and daptomycin; 2. Patients treated with different varieties of vancomycin; 3. Patients with irrational vancomycin use; 4. Pregnant or breastfeeding women; 5. Patients lacking of clinical infection and laboratory evaluation index to be evaluated the clinical efficacy and safety.

Design outcomes

Primary

MeasureTime frame
medication duration;Clinical efficacy;

Secondary

MeasureTime frame
hospitalization days after medication;medical costs;

Countries

China

Contacts

Public ContactLiu Maobai

Fujian Medical University Union Hospital

liumb0591@sina.com+86 591 86218372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026